FDABridge
← Balik sa blog
Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

FDA Stories #012 β€” A Moroccan Argan Oil Exporter Had to Choose: Cosmetic or Food. They Were Selling Both.

The dietary supplement contained a botanical ingredient widely used in Traditional Chinese Medicine. In the United States, it was an unapproved New Dietary Ingredient. The entire shipment was refused.

Koponan ng FDABridgeβ€’Ene 1, 2026β€’3 min na mabasa

A dietary supplement manufacturer in Guangzhou was preparing to export a Traditional Chinese Medicine-inspired supplement capsule to the United States. The product contained a blend of botanical extracts including one ingredient β€” a specific plant extract β€” that had been used in Chinese herbal medicine for centuries and was widely sold as a health product across Asia.

The ingredient had no history of marketing in the United States before October 15, 1994.

Why that date matters

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), any dietary ingredient that was not marketed in the US before October 15, 1994, is classified as a New Dietary Ingredient (NDI). Before marketing a product containing an NDI, the manufacturer or distributor must submit an NDI notification to the FDA at least 75 days before introducing the product. The notification must demonstrate a reasonable expectation of safety based on the ingredient's history of use or other evidence.

The Guangzhou manufacturer had not filed an NDI notification. They assumed that centuries of use in China constituted sufficient safety evidence. Under US law, it does not β€” unless that evidence is compiled in a formal NDI notification and submitted to the FDA. Without the notification, the product containing the NDI is adulterated under Section 402(f) of the FD&C Act.

The refusal

The first shipment β€” 2,000 bottles valued at approximately $28,000 β€” was refused entry at the Port of Long Beach. The FDA's import screening flagged the product because the ingredient appeared on FDA's internal list of NDIs without active notifications. The refusal was immediate. The product was not examined, not tested β€” simply refused based on the ingredient list and the absence of a valid NDI notification in FDA's database.

What we did

We worked with the manufacturer to evaluate their options. Filing an NDI notification would take at least 75 days plus preparation time and would require compiling safety data β€” toxicological studies, published literature, and documentation of the ingredient's history of use. The alternative was to reformulate the product using only ingredients with established US dietary ingredient status. They chose reformulation for speed and filed the NDI notification separately as a longer-term project. The reformulated product entered the US market 8 weeks later.

If you manufacture dietary supplements and you use ingredients sourced from traditional medicine systems β€” Ayurveda, TCM, Unani, Kampo β€” check the NDI status of every ingredient before you ship. fdabridge.com/contact.

Kailangan mo ng tulong sa susunod?

Kailangan ng tulong sa pagpili ng serbisyo?

Ihambing ang mga serbisyo at piliin ang tamang filing path para sa iyong produkto.

Mas marami pang mabasa

Mga kaugnay na artikulo

Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

Mga simbolo sa paglalaman ng medikal na aparato: Ano ang Dapat Malaman ng mga Pang-aalaga sa Kanlurang Bansa Para sa pagpasok sa Mercado ng US

Abr 28, 2026

Ang pagpapalagay ng medikal na aparato sa Estados Unidos ay nangangailangan ng mga tiyak na simbolo para sa tamang komunikasyon. Dapat maunawaan ng mga dayuhang tagagawa ang mga pamantayan ng simbolo na tinatanggap ng FDA bago mag-export ng mga aparato sa merkado ng Amerika.

Magbasa pa β†’
Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

Pagrehistro ng Medikal na Disposisyon para sa mga dayuhang tagagawa: Isang Gawain sa US Regulatory System

Mar 26, 2026

Ang mga tagagawa ng mga medikal na aparato ng dayuhan ay dapat magrehistro ng kanilang mga establisimento, maglista ng kanilang mga aparato, at depende sa klase ng aparato makakuha ng pag-aalis o pahintulot ng FDA bago i-distribute sa Estados Unidos.

Magbasa pa β†’
Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

Sampong Tanong Dapat Itanong Bago Mag-upa ng isang Konsultor ng FDA

May 24, 2026

Ang pagpili ng isang tagapagbigay ng serbisyo sa pagsunod sa FDA ay isang resulta ng desisyon. Ang sampung tanong na ito ay tumutulong sa mga dayuhang tagagawa na ihiwalayin ang mga may kakayahan na konsultante mula sa mga magtataguyod ng mga problema na hindi nila maiiwasan.

Magbasa pa β†’